title: Autologous platelet lysate for treatment of refractory ocular GVHD.
abstract: Current treatment of ocular GVHD (oGVHD), represented by systemic immunosuppressive regimens and local therapies (mainly artificial tears and corticosteroids), gives unsatisfactory results. We investigated the safety and efficacy of autologous plasma rich in PDGFs to treat oGVHD unresponsive to standard medications. A total of 23 patients with refractory oGVHD (grade II-IV) unresponsive to standard therapy were treated with autologous plasma rich in PDGFs eye drops (PRGD) four times/day for 6 months. Symptoms and signs (best visual acuity, Schirmer's test and tear break up time (TBUT), evaluation of the anterior segment and fluorescein and lissamine staining) were always assessed by the same ophthalmologist. Patients were defined as 'responders' when showing improvement for total complaints and at least one sign. At 30 days of treatment, 17 patients (73.9%) were classified as responders. The symptom that improved most was photophobia (improved in 19 patients, 82.6%). TBUT improved in 20 patients (86.9%) and anterior segment score in 19 patients (82.6%). Response was maintained over time. No serious adverse events occurred. PRGD proved to be safe and effective in treating oGVHD and may be a valid treatment option from the early stages of the disease to avoid irreversible ocular damage.
authors.affiliation: Department of Ophthalmology, University Eye Clinic of Pavia, IRCCS Policlinico S Matteo Foundation, Pavia, Italy. sara.pezzotta@libero.it
authors.forename: S
authors.initials: S
authors.lastname: Pezzotta
authors.forename: C
authors.initials: C
authors.lastname: Del Fante
authors.forename: L
authors.initials: L
authors.lastname: Scudeller
authors.forename: M
authors.initials: M
authors.lastname: Cervio
authors.forename: E R
authors.initials: ER
authors.lastname: Antoniazzi
authors.forename: C
authors.initials: C
authors.lastname: Perotti
mesh_terms: D000328:Adult; D000368:Aged; D015352:Dry Eye Syndromes / Q000276:immunology / Q000628:therapy*; D005260:Female; D006086:Graft vs Host Disease / Q000276:immunology / Q000628:therapy*; D019337:Hematologic Neoplasms / Q000601:surgery; D006801:Humans; D008297:Male; D008875:Middle Aged; D010982:Platelet-Derived Growth Factor / Q000008:administration & dosage*; D053657:Platelet-Rich Plasma / Q000737:chemistry*; D033581:Stem Cell Transplantation / Q000009:adverse effects
chemical_list: D010982:Platelet-Derived Growth Factor